Showing results (61-70 of 105) with videos related to
Sort By:
Pageof 11
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.JAMA Internal Medicine|October 1, 2020
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical TrialBenjamin S Abella, Eliana L Jolkovsky, Barbara T Biney, et al.Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myelomaRavi Vij, Shaji Kumar, Mei-Jie Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2009
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl, Margaret T Kasner, Donald E Tsai, et al.The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.Clinical Chemistry|August 12, 2021
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and TrackingHui Chen, Zhao Li, Sheng Feng, et al.Pageof 11